Table 3.

Analysis of deprescribing criteria for each therapeutic class.

Criteriaa		PPI	NSAID	OPI	BZN
Total number of deprescribing candidates (n, % of users)		n = 38/122 (31.1%)	n = 83/111 (74.8%)	n = 45/60 75.0% (75.0%)	96.1% n = 148/154 (96.1%)
Lack of indication (n, % of users)		n = 9/122 (7.4%)	0	18.3% n = 11/60 (18.3%)	n = 38/154 (24.7%)
Inappropriately long use (n, % of users)		n = 32/122 (26.2%)	n = 58/111 (52.3%)	n = 42/60 70.00% (70.00%)	n = 94/154 (61.0%) for insomnia use n = 73/154 (47.71%) for anxiety use
Inappropriate dose (n, % of users)		n = 20/122 (16.4%) inappropriately high gastroprotective dose	n = 19/111 (17.1%) higher than recommended daily dose	0	n = 26/154 (17.0%) higher than recommended daily dose
Safety concerns (n, % of users)	Potential clinically significant DDI	n = 3/122 (2.5%)	n = 36/111 (32.4%)	n = 31/60 (51.7%)	n = 39/154 (25.5%)
	Presence of ADE		n = 45/111 (40.5%)	n = 32/60 (56.3%)	n = 81/154 (52.6%)
	Pther safety concerns		n = 35/111 (30.97%) with factors which could be exacerbated by NSAID use	0	n = 56/154 (36.6%) frailty score 4 and above

^aPatient could meet multiple deprescribing criteria for a single therapeutic class, PPI—proton pump inhibitors, NSAID—nonsteroidal anti-inflammatory drugs, OPI-opioid analgesics, BZN—benzodiazepine receptor agonists, DDI—drug-drug interaction, ADE—adverse drug effects, pro re nata use was noted in 4.09% (n = 5/122) PPI users, 18.92% (n = 21/111) NSAID users, 23.33% (n = 14/60) OPI users, and in 26.80% (n = 41/154) BZN users.

Siginificant values are in bold.